» Articles » PMID: 28982149

The Interplay of CD150 and CD180 Receptor Pathways Contribute to the Pathobiology of Chronic Lymphocytic Leukemia B Cells by Selective Inhibition of Akt and MAPK Signaling

Overview
Journal PLoS One
Date 2017 Oct 6
PMID 28982149
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Cell surface expression of CD150 and CD180 receptors in chronic lymphocytic leukemia (CLL) associates with mutational IGHV status and favourable prognosis. Here we show a direct correlation between cell surface expression and colocalization of these receptors on CLL B cells. In the absence of CD150 and CD180 on the cell surface both receptors were expressed in the cytoplasm. The CD150 receptor was colocalized with markers of the endoplasmic reticulum, the Golgi apparatus and early endosomes. In contrast, CD180 was detected preferentially in early endosomes. Analysis of CD150 isoforms differential expression revealed that regardless of CD150 cell surface expression the mCD150 isoform with two ITSM signaling motifs was a predominant CD150 isoform in CLL B cells. The majority of CLL cases had significantly elevated expression level of the soluble sCD150, moreover CLL B cells secrete this isoform. CD150 or CD180 crosslinking on CLL B cells alone led to activation of Akt, mTORC1, ERK1/2, p38MAPK and JNK1/2 networks. Both CD150 and CD180 target the translation machinery through mTOR independent as well as mTOR dependent pathways. Moreover, both these receptors transmit pro-survival signals via Akt-mediated inhibition of GSK3β and FOXO1/FOXO3a. Unexpectedly, coligation CD150 and CD180 receptors on CLL B cells led to mutual inhibition of the Akt and MAPK pathways. While CD150 and CD180 coligation resulted in reduced phosphorylation of Akt, ERK1/2, c-Jun, RSK, p70S6K, S6RP, and 4E-BP; it led to complete blocking of mTOR and p38MAPK phosphorylation. At the same time coligation of CD150 and CD40 receptors did not result in Akt and MAPK inhibition. This suggests that combination of signals via CD150 and CD180 leads to blocking of pro-survival pathways that may be a restraining factor for neoplastic CLL B cells propagation in more than 50% of CLL cases where these receptors are coexpressed.

Citing Articles

Comprehensive analysis of signaling lymphocyte activation molecule family as a prognostic biomarker and correlation with immune infiltration in clear cell renal cell carcinoma.

Song N, Wang Z, Shi P, Cui K, Fan Y, Zeng L Oncol Lett. 2024; 28(2):354.

PMID: 38881710 PMC: 11176890. DOI: 10.3892/ol.2024.14487.


The role of CD180 in hematological malignancies and inflammatory disorders.

Edwards K, Lydyard P, Kulikova N, Tsertsvadze T, Volpi E, Chiorazzi N Mol Med. 2023; 29(1):97.

PMID: 37460961 PMC: 10353253. DOI: 10.1186/s10020-023-00682-x.


SLAM-family receptors come of age as a potential molecular target in cancer immunotherapy.

Farhangnia P, Ghomi S, Mollazadehghomi S, Nickho H, Akbarpour M, Delbandi A Front Immunol. 2023; 14:1174138.

PMID: 37251372 PMC: 10213746. DOI: 10.3389/fimmu.2023.1174138.


The Potential Role of RP105 in Regulation of Inflammation and Osteoclastogenesis During Inflammatory Diseases.

Fan Z, Pathak J, Ge L Front Cell Dev Biol. 2021; 9:713254.

PMID: 34414191 PMC: 8369417. DOI: 10.3389/fcell.2021.713254.


SLAMF1 Promotes Methotrexate Resistance via Activating Autophagy in Choriocarcinoma Cells.

Shi D, Zhang Y, Tian Y Cancer Manag Res. 2021; 12:13427-13436.

PMID: 33408515 PMC: 7779304. DOI: 10.2147/CMAR.S278012.


References
1.
Sidorenko S, Vetrova E, Yurchenko O, Berdova A, Shlapatskaya L, Gluzman D . Monoclonal antibodies of IPO series against B cell differentiation antigens in leukemia and lymphoma immunophenotyping. Neoplasma. 1992; 39(1):3-9. View

2.
Porakishvili N, Vispute K, Steele A, Rajakaruna N, Kulikova N, Tsertsvadze T . Rewiring of sIgM-Mediated Intracellular Signaling through the CD180 Toll-like Receptor. Mol Med. 2015; 21(1):46-57. PMC: 4461575. DOI: 10.2119/molmed.2014.00265. View

3.
Mavaddat N, Mason D, Atkinson P, Evans E, Gilbert R, Stuart D . Signaling lymphocytic activation molecule (CDw150) is homophilic but self-associates with very low affinity. J Biol Chem. 2000; 275(36):28100-9. DOI: 10.1074/jbc.M004117200. View

4.
Yurchenko M, Shlapatska L, Romanets O, Ganshevskiy D, Kashuba E, Zamoshnikova A . CD150-mediated Akt signalling pathway in normal and malignant B cells. Exp Oncol. 2011; 33(1):9-18. View

5.
Huang P, Best O, Almazi J, Belov L, Davis Z, Majid A . Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia. Leuk Lymphoma. 2013; 55(9):2085-92. DOI: 10.3109/10428194.2013.867486. View